Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies

• Derek J. Nunez ,

  * E-mail: derek.j.nunez@gsk.com

  Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

  ⨯
• Mark A. Bush,

  Current address: Nuventra Pharma Sciences, Durham, North Carolina, United States of America

  Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

  ⨯
• David A. Collins,

  Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

  ⨯
• Susan L. McMullen,

  Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

  ⨯
• Dawn Gillmor,

  Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

  ⨯
• Glen Apseloff,

  Affiliation Ohio State University Clinical Pharmacology Unit, Columbus, Ohio, United States of America

  ⨯
• George Atiee,

  Affiliation Worldwide Clinical Trials, San Antonio, Texas, United States of America

  ⨯
• Leonor Corsino,

  Affiliation Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Linda Morrow,

  Affiliation Profil Institute for Clinical Research, Chula Vista, California, United States of America

  ⨯
• Paul L. Feldman

  Affiliation GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America

  ⨯